Key Drivers
- Positive Cash Flow
- Elevated Debt Burden
- Persistent Net Losses
AIAI Summary
SGRY is now a deleveraging and post-divestiture execution story: the Idaho Falls sale can reduce leverage and interest expense, but investors should wait for proof that the smaller remaining platform can sustain organic EBITDA and free-cash-flow growth without renewed debt-funded acquisitions.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive Cash Flow
- •Elevated Debt Burden
- •Persistent Net Losses
SGRY generates solid cash flow and has adequate liquidity, but heavy leverage, persistent losses, weak returns, and intangible-asset concentration make it a high-risk value proposition.
Price Behavior
Key Price Behavior Insights:
- •Fresh period low
- •Weak momentum
- •Key $14 recovery
SGRY is bearish after an 8.7% last-month decline, with $13.25 as unconfirmed support and a recovery above $14.00 needed to improve momentum.
Closed at a fresh period low despite nearing potential support
Sentiment & News
Key News Insights:
- •BlackRock Stake
- •Insider Purchase
- •Asset Divestiture
Surgery Partners gained investor confidence through major BlackRock and insider purchases while divesting Idaho Falls assets and updating guidance.
The combined buying activity is supportive, though revised guidance following the divestiture remains a key catalyst
Similar Companies in Healthcare
Other companies in the same sector with AI ratings